Skip to content

Biomarkers for the diagnosis and prognosis of autoimmune encephalitis

Biomarkers for the diagnosis and prognosis of autoimmune encephalitis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400083220
Enrollment
Unknown
Registered
2024-04-18
Start date
2024-04-30
Completion date
Unknown
Last updated
2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune encephalitis

Interventions

Autoimmune encephalitis group:No interventions
Non-inflammatory, non-immune control group:No interventions

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) At least meet the diagnostic criteria of "possible autoimmune encephalitis" proposed by Graus et al. in The Lancet in 2016. (2) Antibody-positive patients are defined as those with unambiguous detection of autoimmune encephalitis antibodies in cerebrospinal fluid and/or serum. (3) Patients with negative antibodies but suspected autoimmune encephalitis should meet the diagnostic criteria of "autoantibody-negative but probable autoimmune encephalitis" proposed by Graus et al. in The Lancet in 2016. (4) Acute phase, onset whthin 6 months.

Exclusion criteria

Exclusion criteria: (1) Patients who lack key clinical data or adequate amounts of biological specimens; (2) Patients with a diagnosis of human immunodeficiency virus (HIV) infection, brain abscess, viral disease, cerebral malaria, brain tumor, or non-communicable central nervous system disease such as acute demyelinating encephalomyelitis (ADEM); (3) Patients with central nervous system infection with bacteria, fungi, parasites or Mycobacterium tuberculosis (TB); (4) Patients with encephalopathy secondary to sepsis or systemic inflammatory response syndrome; (5) Subjects with history of other autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes, etc.)

Design outcomes

Primary

MeasureTime frame
Modified Rankin Scale;

Secondary

MeasureTime frame
CASE score;Montreal Cognitive Assessment;

Countries

China

Contacts

Public ContactZhen Hong

West China Hospital, Sichuan University

hongzhengoog@aliyun.com+86 189 8060 5818

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026